Metabolic Mechanisms in Epileptic Disorders

Epileptic disorders arise from neuronal hyperexcitability and synchronised discharges, processes that demand tightly regulated energy supply and ionic homeostasis. Emerging evidence has revealed that alterations in glucose uptake, glycolytic flux and mitochondrial oxidative metabolism contribute directly to seizure genesis and propagation. Impaired function of key enzymes such as pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase leads to reduced ATP production, destabilisation of neuronal membrane potentials and aberrant neurotransmission. Concurrently, adaptive shifts to alternative substrates, notably ketone bodies and medium-chain fatty acids, can restore energy balance and stabilise network excitability. Metabolic interventions including ketogenic diets, low-glycaemic index treatments and targeted inhibitors of glycolysis have been shown to modulate neurosteroid synthesis, γ-aminobutyric acid transmission and ion-channel function, thereby offering complementary routes to pharmacological therapy. Additionally, genetic forms of epilepsy linked to ion-channel mutations demonstrate distinctive metabolic signatures, suggesting that personalised metabolic support may augment precision medicine approaches. Innovations in nanoparticle and dendrimer technologies further promise to deliver metabolic agents selectively to hyperexcitable cells, minimising off-target effects. This growing synthesis of bioenergetics, neuropharmacology and molecular genetics underscores the global significance of metabolic mechanisms in epilepsy and paves the way for novel therapeutics that address the energetic substrates of seizure disorders.

Research from Nature Portfolio

Recent studies have demonstrated that selective inhibition of glycolysis can reverse circuit dysfunction in temporal lobe epilepsy. In rodent models, administration of 2-deoxy-D-glucose during established seizure activity restored oscillatory power and coherence between the dorsal hippocampus and basolateral amygdala, particularly in gamma frequencies linked to anxiety-like behaviour. This metabolic intervention not only normalised local field potentials but also mitigated seizure-related comorbidities, illustrating the therapeutic potential of targeting early steps in glucose metabolism to recalibrate aberrant neural networks.

Metabolic Mechanisms in Epileptic Disorders publication trend

The graph below shows the total number of articles in metabolic mechanisms in epileptic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Glycolysis: The metabolic pathway converting glucose into pyruvate with net production of ATP and NADH in the cytosol.

Oxidative phosphorylation: The mitochondrial process coupling electron transport to ATP synthesis via the tricarboxylic acid cycle and respiratory chain.

Ketone bodies: Energy substrates such as β-hydroxybutyrate and acetoacetate generated from fatty acids during low-carbohydrate states.

2-Deoxy-D-glucose (2-DG): A glucose analogue that inhibits glycolysis by blocking hexokinase, reducing cellular ATP production.

Allopregnanolone: A neurosteroid derived from progesterone that enhances GABA_A receptor-mediated inhibition.

Glucose-dendrimer: A branched polymer scaffold composed of glucose units designed for targeted delivery of therapeutic agents to neurons.

References

1. Low glycemic index diet restrains epileptogenesis in a gender-specific fashion. Cellular and Molecular Life Sciences (2023).
2. Development of a novel glucose‐dendrimer based therapeutic targeting hyperexcitable neurons in neurological disorders. Bioengineering & Translational Medicine (2024).
3. Glycolysis inhibition partially resets epilepsy-induced alterations in the dorsal hippocampus-basolateral amygdala circuit involved in anxiety-like behavior. Scientific Reports (2023).
4. Metabolic aspects of genetic ion channel epilepsies. Journal of Neurochemistry (2023).